Novo Struggles In Japan, Sanofi Struggles With Distributors: Emerging Markets Earnings Roundup (Part 7)
This article was originally published in PharmAsia News
Executive Summary
Both Novo Nordisk and Sanofi had a bumpy start of the year in Asia and emerging markets. Novo saw insulin sales decline in Japan and Korea, while Sanofi grew only 6.5% in emerging markets, well below the company’s long-term guidance of double-digit growth.
You may also be interested in...
Sanofi Revamps Commercial Ops, Prioritizes Fixed-Ratio Lantus-Lyxumia Combo
Sanofi plans to split its commercial organization into two units as the French drug giant starts to emerge from its patent cliff with a return to growth and a renewed focus on new diabetes therapies.
Novo Nordisk Dismayed By “Complete Response” Letter For Insulin Degludec
FDA is requesting data from a dedicated cardiovascular outcomes trial before approving the ultra-long-acting insulins Tresiba and Ryzodeg. News of the regulatory setback caused a 13% drop in the company’s stock price on Feb. 11.
Sanofi Expands China Footprint In OTC And Rx Markets With BMP Sunstone Acquisition
Sanofi-Aventis has gained a leadership position in China's OTC cough/cold market with its $520.6 million acquisition of BMP Sunstone, the latest in the global pharma's parade of consumer health buys